| 31.935 -0.055 (-0.17%) | 08-11 12:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.77 | 1-year : | 46.45 |
| Resists | First : | 34.04 | Second : | 39.77 |
| Pivot price | 31.66 |
|||
| Supports | First : | 29.41  |
Second : | 26.54 |
| MAs | MA(5) : | 31.93 |
MA(20) : | 31.26 |
| MA(100) : | 22.98 |
MA(250) : | 24.85 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 60 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 44.59 | Low : | 13.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZBIO ] has closed above bottom band by 31.8%. Bollinger Bands are 56.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 32.72 - 32.89 | 32.89 - 32.99 |
| Low: | 31.21 - 31.43 | 31.43 - 31.57 |
| Close: | 31.68 - 32.01 | 32.01 - 32.22 |
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Fri, 07 Aug 2026
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review
Fri, 07 Aug 2026
Zenas BioPharma, Inc. (ZBIO): Investor Outlook On A Potential 35% Upside - DirectorsTalk Interviews
Fri, 07 Aug 2026
Zenas BioPharma (ZBIO) Institutional Ownership 2026 - MarketBeat
Tue, 28 Jul 2026
Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Tue, 14 Jul 2026
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO) - Seeking Alpha
Fri, 10 Jul 2026
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 18.2 (%) |
| Held by Institutions | 93 (%) |
| Shares Short | 12,170 (K) |
| Shares Short P.Month | 11,130 (K) |
| EPS | -9.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.1 % |
| Return on Equity (ttm) | -137.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -166 (M) |
| PE Ratio | -3.43 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|